Metabolon Launches Bile Acids and Short Chain Fatty Acids Targeted Panels to Advance Understanding of Microbiome and Gut Metabolome in Health and Disease
Retrieved on:
Tuesday, April 4, 2023
FXR, Diet, Diabetes, Cholesterol, Lipid, Metabolomics, Physiology, Fermentation, TGR5, Research, Biomarker, Microbiota, Colon, Inflammatory bowel disease, Short, SFCA Lignel 46 Coach, Content discovery platform, Risk, Cancer, Medicine, SCFA, Biology, Liver, Extrapyramidal system, Health, Phenotype, Neurology, Disease, Medical imaging, Dietary supplement, Pharmaceutical industry, Metabolon
MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Bile Acids and Short Chain Fatty Acids Targeted Panels that measure microbially-derived metabolites of biological significance to identify biomarkers for the prediction and early detection of disease areas, including oncology, neurology, liver, diabetes, and gastrointestinal, and gut health.
Key Points:
- Short Chain Fatty Acids (SCFAs) are produced in the colon by the gut microbiota and are the end products of the anaerobic fermentation of dietary fibers and protein/peptides in the small intestine.
- Metabolon's Bile Acids Targeted Panel measures 21 metabolites and has been designed specifically to advance pre-clinical research identifying bile-acid related biomarkers in digestive, metabolic, and neurological health.
- "Metabolon is committed to advancing scientific understanding of the human microbiome and its impact on human health.
- Our Bile Acids and Short Chain Fatty Acids Targeted Panels address an important need for today's cutting-edge researchers and will help unlock new insights into the complex interplay between diet, gut health, and disease, paving the way for the development of more personalized, targeted therapies."